As of June 4, 2025, Rhythm Pharmaceuticals Inc (RYTM) reports a Net Margin of -200.27%.
Net Margin shows the share of revenue that becomes profit after all costs, reflecting overall profitability.
Historical Trend of Rhythm Pharmaceuticals Inc's Net Margin
Over recent years, Rhythm Pharmaceuticals Inc's Net Margin has shown a stable trend. The table below summarizes the historical values:
| Date | Net Margin |
|---|---|
| 2024-12-31 | -200.27% |
| 2023-12-31 | -238.52% |
| 2022-12-31 | -766.16% |
| 2021-12-31 | -2209.84% |
This steady improvement highlights how Rhythm Pharmaceuticals Inc manages its overall profitability and cost control over time.
Comparing Rhythm Pharmaceuticals Inc's Net Margin to Peers
To better understand Rhythm Pharmaceuticals Inc's position, it's useful to compare its Net Margin against industry peers. Below are selected comparisons:
| Company | Net Margin |
|---|---|
| Rhythm Pharmaceuticals Inc (RYTM) | -200.27% |
| Regeneron Pharmaceuticals Inc (REGN) | 31.07% |
| Amgen Inc (AMGN) | 12.24% |
| Dynavax Technologies Corp (DVAX) | 9.85% |
| Abbvie Inc (ABBV) | 7.59% |
| Gilead Sciences Inc (GILD) | 1.67% |
Compared to its competitors, Rhythm Pharmaceuticals Inc's Net Margin is about average compared to peers, reflecting typical industry profitability.